U.S. Government Places $26 Million Order for Siga’s Monkeypox Drug

The U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) has placed a $26 million order for Siga Technologies’ intravenous Tpoxx treatment for monkeypox infections.

The intravenous drug offers an alternative treatment option for patients who have difficulty swallowing the oral formulation of the drug.

Tpoxx (tecovirimat) is FDA-approved to treat smallpox in adults and children. There are currently no FDA-approved or FDA-authorized drugs indicated for the treatment of monkeypox. However, the investigational drug can be prescribed by doctors for monkeypox patients using the FDA’s expanded access program.

The company expects to deliver the first shipments of intravenous Tpoxx in 2023.